Insulin-like growth factor 1 receptors in human breast tumour: Localisation and quantification by histo-autoradiographic analysis

H. Jammes¹, J.-P. Peyrat², E. Ban¹, M.-O. Vilain², F. Haour¹, J. Djiane¹ & J. Bonneterre²

¹Unité d’Endocrinologie Moléculaire, INRA, 78350 Jouy-en-Josas; ²Laboratoire d’Endocrinologie Expérimentale Centre Oscar Lambret, BP 307, 59020 Lille Cédex; ³Laboratoire de Pharmacologie Neuro-Immuno-Endocrinienne, CNRS UA 1113, Institut Pasteur, 75724 Paris Cédex 15, France.

Summary To assess the precise role of IGF1 in benign and malignant breast diseases, we analysed the tissular localisation, characterised, and quantified specific insulin-like growth factor 1 (IGF1) binding sites in these heterogeneous tissues, using histo-autoradiographic analysis (HAA). The ¹²⁵I-IGF1 binding was performed on frozen tissue sections and analysed using ¹²⁵I Ultratome autoradiography coupled to computerised image analysis. Competitive binding experiments using unlabelled IGF1, IGF3 and insulin showed that the tissues exhibited typical type I IGF binding sites. This specificity was confirmed by the use of alpha 1R-3 monoclonal antibody, as inhibitor of ¹²⁵I-IGF1 binding. IGF1 binding sites were detected in 18 human primary breast cancers, 12 benign breast tumours and two normal breast tissues. Using HAA we found that the human breast carcinomas studied exhibit a specific and high binding capacity for ¹²⁵I-IGF1 exclusively localised on the proliferative epithelial component. The ¹²⁵I-IGF1 binding activity of benign breast tumours or normal breast tissue was significantly lower than in cancerous tissues. There was a significant correlation between IGF1-R concentrations detected with HAA and those detected with a classical biochemical method. Moreover, HAA could be useful in further detailing whether a tumour is IGF1-R positive or negative HAA appears to be a useful method for the detection of growth factor receptors, specially in small biopsy specimens.

Insulin-like growth factor (IGF1), also termed somatomedin C, is a small polypeptide (M.W. 7400 daltons) whose primary physiological role is to act on skeletal development via the endocrine pathway, together with growth hormone (Furnaletto et al., 1977; Zapf & Froesch, 1986). This factor stimulates the growth of many cell types (Moses & Pilistine, 1985), including various breast cancer cell lines (Furnaletto & Di Carlo, 1984; Myal et al., 1984; Huff et al., 1986; Dickson & Lippman, 1987; Karey & Sirbasku, 1988). IGF1 is synthesised in many tissues (D’Ercole et al., 1984; Murphy et al., 1987; Lund et al., 1986) and immunoreactive IGF1 had been found in the medium conditioned by breast cancer cell lines (Baxter et al., 1983; Huff et al., 1986; Minuto et al., 1987). The recent demonstration of the absence of IGF1 mRNA in these cells suggests that ‘immunoreactive IGF1’ represents either IGF1-related proteins or secreted IGF1 binding proteins (Yee et al., 1989). The presence of IGF1 mRNA in breast cancers evokes a paracrine role of this factor (Yee et al., 1989).

The first step in IGF1 action is its binding to membrane receptors (Rosenfeld & Hintz, 1988). IGF1 binding sites have been characterised by competitive binding and cross-linking techniques in breast cancer cell lines (Furnaletto & Di Carlo, 1984; Myal et al., 1984; De Leon et al., 1988; Pollack et al., 1988; Peyrat et al., 1989) as well as in breast cancers (Peyrat et al., 1988a) or in benign breast diseases (Peyrat et al., 1988b). We demonstrated that IGF2 was a good competitor of the binding of ¹²⁵I-IGF1 to IGF1-R whereas insulin competed with a potency lower than 1/100th of IGF1’s potency. Chemical cross-linking experiments revealed that the apparent molecular weight of the binding site was 130,000 daltons (Peyrat et al., 1988a). Therefore, the IGF1 specific binding sites share a close structural homology with insulin receptor and correspond to the previously described type I IGF receptors (IGF1-R) in normal tissues. It has recently been shown that the mitogenic effect of IGF2 on breast cancer epithelial cell lines (Karey & Sirbasku, 1988; Yee et al., 1988) could be mediated, at least partially, by IGF1-R (Osborne et al., 1989; Cullen et al., 1990).

Several authors have demonstrated that most breast cancers contain IGF1-R (Peyrat et al., 1988a; Pollack et al., 1987; Pekonen, 1988; Fockens et al., 1989). In our study, the presence of IGF1-R is associated to a better prognosis (Bonneterre et al., 1990). Conversely, IGF1-R are found less frequently and at lower concentrations in benign breast diseases (Peyrat et al., 1988b). These results suggest that IGF1-R could be a marker of the proliferative epithelial component inside the tumour. However, all of these studies had been performed using membrane preparations, which do not allow the precise localisation of binding sites in a heterogeneous tissue such as breast cancer. The development of techniques based on autoradiography, and specially of quantitative densitometry analysis, has allowed the localisation of receptors, and particularly of IGF1-R, in different heterogeneous tissues such as the brain (Israel et al., 1984; Bohannon et al., 1986), the adrenal gland (Shigematsu et al., 1989) and the ovary (Monget et al., 1989).

We have used this technique to specify the localisation and to quantify high affinity IGF1-R in benign and malignant human breast tumours.

Patients, materials and methods

Tumour collection

Tumour specimens were obtained from patients undergoing surgery for primary breast cancer or benign breast tumour in the Centre Oscar Lambret (Lille, France). At the time of collection fat was removed and samples were divided into three parts. One portion was submitted to histological analysis, while the others were immediately frozen in liquid nitrogen until histo-autoradiographic analysis (HAA) and biochemical receptor determinations.

Our series was composed of 13 ductular, two lobular, one colloid, one ductular lobular and one comedo invasive carcinoma, of six dystrophy, five fibroadenomas, and one phyllid tumour. Two normal breasts was also analysed.

IGF1 labelling

Human synthetic IGF1 was purchased from Eli Lilly Company (Indianapolis, USA). A modification of the method of Hunter and Greenwood, using a low concentration of chloramine T, was employed to iodinate IGF1 (Peyrat et al., 1988a). Specific activity, as calculated by isotope recovery,
was 2,000 Ci mmole⁻¹. The quality of the labelled IGF1 was checked after each iodination using a standard laboratory preparation of BT-20 breast cancer cell-line membrane receptors. The tracer was considered usable when 400 μg of the usual protein membrane preparation specifically bound 10% of the iodinated IGF1 (Peyrat et al., 1988a).

Quantitative IGF1-R autoradiography

Frozen sections (7 μm) were processed as previously described (Haurou et al., 1987). Briefly the slide-mounted sections were pre-incubated for 10 min at 20°C in 'Tris-HCl' buffer (Tris 50 mM; pH 7.4) containing 2 mM CaCl₂ and 5 mM KCl. The sections were then washed twice with 'Tris-HCl' buffer. Incubation was carried out at 20°C for 30 min in Tris-HCl (120 mM; pH 7.4) containing 0.1% BSA and 0.45 nm [¹²⁵I]-IGF1 (10⁵ cpm ml⁻¹) according to the experimental conditions described by Bohanon et al. (1986) and Shigematsu et al. (1989). Non-specific binding was determined in the presence of 5 × 10⁻⁷ M IGF1. In some cases, the competition was achieved with alpha IR3 monoclonal antibody (purchased from CliniSciences, France) that specifically blocks breast cancer IGF1-R (Pollak et al., 1988; Rohlik et al., 1987; Arteaga & Osborne, 1989). After pre-incubation of cryostat sections in the presence or absence of 10 μg ml⁻¹ of alpha IR3 monoclonal antibody buffer for 1 h at 20°C, the sections (7 μm) were washed three times for 10 min in ice-cold Tris-HCl buffer (50 mM), dried, and exposed for 7 days to Amersham autoradiographic films (³H-hyperfilm). The films were processed and the relative density of [¹²⁵I]-IGF1 binding sites was quantified by computerised densitometry using an image analyser (RAG 200, BIOCOM, Les Ulis, France). It was related to the concentration of radioactivity as based on a comparison with standard curves generated by processing sets of Amersham [¹²⁵I]-microscale; the results were expressed in femtomoles of ligand bound per milligram of proteins (Israel et al., 1984). Normal human liver was used as negative control as it is an abundant producer of IGF1 binding protein but expresses very little type I IGF receptor.

Biochemical IGF1 receptor assay

The frozen tissue was weighed and then pulverised (Spx-Bioblock France). The tissues were homogenised in 20 mM Tris HCl, 3 mM EDTA, 1 mM diithiothreitol, 0.01% azide, pH 7.6. The homogenate was centrifuged at 800 g for 10 min and the supernatant (cytosol) was ultracentrifuged at 105,000 g for 60 min. The supernatant (cytosol) was removed and the pellet (‘microsomal’ fraction) was resuspended in 25 mM Tris-HCl, 10 mM MgCl₂, 0.1 mM phenylmethylsulfonyl fluoride, pH 7.6 (Tris-MgCl₂ buffer). The protein concentration was determined by the method of Lowry et al. (1951) applied either directly in the cytosol fraction, or after extraction from the membranes (with NaOH 1 N) in the microsomal fraction.

The binding test was described previously (Peyrat et al., 1988a): 400 μg of membrane proteins were incubated for 5 h at 4°C with approximately 200,000 cpm of iodinated IGF1 in the presence or absence of an excess of unlabelled IGF1. The final incubation volume was adjusted to 0.5 ml with Tris-MgCl₂ buffer containing 0.1% bovine serum albumin (fraction V, ref. A3912, Sigma Chemical Company, St. Louis, MD, USA). Bound receptors were separated by a 3,000 g, 30 min. centrifugation. In our experimental conditions, the iodinated ligand was not saturating and the [¹²⁵I]-IGF1 specific binding was expressed as a percentage of total radioactivity.

Results

Autoradiographic analysis and characterisation of IGF1-R

The binding specificities of [¹²⁵I]-IGF1 to the breast cancer sections are analysed in several tumours and shown in Figure 1a. [¹²⁵I]-IGF1 binding to the receptor was inhibited by unlabelled IGF1 (10⁻¹¹ to 10⁻⁷ M) in a concentration dependent manner. The non-specific binding obtained in the presence of an excess of IGF1 (5 × 10⁻⁷ M), represented 25% of [¹²⁵I]-IGF1 total binding. IGF2, in the same concentrations (10⁻⁹ to 10⁻⁷ M), also displaced [¹²⁵I]-IGF1 binding. In our experimental conditions, insulin competed for IGFI receptor, but was much less efficient than IGF1. When the non-specific binding was determined using alpha IR-3, the mouse monoclonal antibody that is highly specific for IGF1 receptor (Rohlik et al., 1987; Pollak et al., 1988; Arteaga & Osborne, 1989), 72% of total [¹²⁵I]-IGF1 binding was inhibited by alpha IR3 (Figure 1a). The data in Figure 1b show the saturation curves of the [¹²⁵I]-IGF1 binding as a function of the labelled IGF1 concentration in two breast carcinoma cases. As illustrated, the high binding was associated with a higher maximum binding capacity (Bmax, femtologs⁻¹ of protein) without a modification of affinity (a Kd approximate value of 1.5 nM).

Cellular localisation and quantification of [¹²⁵I]-IGF1 specific binding

Breast tumours are heterogeneous tissues composed of epithelial cells, connective tissue, fibroblasts and adipocytes. The autoradiographic analysis made possible the characterisation and mapping of [¹²⁵I]-IGF1 specific binding in several
biopsies. Figure 2 shows typical examples of histo-auto-
radiograms obtained by $^{125}$I-IGF1 binding on ductular breast
cancer sections. The densitometric autoradiographic analysis
of the whole section of the tumours allowed the quanti-
fication of global total binding (44.8 fmoles mg$^{-1}$ protein,
Figure 2a) and non-specific binding (12.2 fmoles mg$^{-1}$ protein,
Figure 2b). The specific binding was 32.6 fmoles mg$^{-1}$ protein.
However, the staining was not uniform. Some areas
contained a high density of IGF1-R and others a very low
density. It is possible to quantify the total binding and the
non-specific binding for each area and to determine the
corresponding tissue component. The area which showed a
high density of specific binding (total binding: 65 fmoles
mg$^{-1}$ protein; non-specific binding: 15 fmoles mg$^{-1}$ protein)
exclusively contained proliferative epithelial cells as shown in
Figure 2c. The areas where IGF1 specific binding was very
low or undetectable (total binding: 26 fmoles mg$^{-1}$ protein,
specific binding: 7 fmoles mg$^{-1}$ protein) were associated to
connective tissue. A very high non-specific IGF1 binding was
observed in the central area corresponding to residual necro-
sis in a mammary duct.

Figure 3 shows autoradiographic images of $^{125}$I-IGF1 in
the adjacent mastosis tissue of the same ductular breast
cancer. The specific binding in the whole section was 0.4

![Figure 2](image_url)
fmoles mg⁻¹ protein (Total binding: 7.7 fmoles mg⁻¹ protein; non-specific binding: 7.3 fmoles mg⁻¹ protein) and the staining was uniform. In this tissue, the histologic analysis revealed an absence of proliferative epithelial cells.

Thirty tumours and two normal breast tissues were analysed for the presence of IGF1-R. The comparison of the biochemical and autoradiographic analysis of IGF1 specific binding was performed for all biopsies tumours except the colloid one for which the membrane preparation was not possible (HAA value: 30 fmoles mg⁻¹ of proteins). To establish this correlation, the results of some detection in non-breed tissue were also included. The pairs of values observed by the biochemical and autoradiographic analysis were respectively: for two samples of tumoral endometrium (8.27/63.4; 2.83/212), for the ovary tumour (2.41/74.6), for the normal liver (0.94/9.36) and for the tumoral liver (3.96/84.2).

Figure 4 shows the correlation between the results obtained, demonstrating a highly significant positive correlation between the two methods. Using the biochemical method we considered that tumours were negative when the specific binding was lower than 1% (Peyrat et al., 1988b). Using this criterion, six tumours were found to be negative, with the more sensitive autoradiographic method, IGF1 specific binding was detectable in the same tumours.

The specific IGF1 binding, in the breast cancers, was particularly high and had a wide range in the breast cancers. The median concentration was 30 fmoles mg⁻¹ of proteins (50% of values were between 19 and 60 fmoles mg⁻¹ of proteins, range 1.9–114). It was significantly higher (p < 0.001) than the median concentration in benign disease (0.7 fmoles mg⁻¹ of proteins; 50% of values were between 0.5 and 0.9 fmoles mg⁻¹ of proteins, range 0–8.6). In the two normal breast tissues studied, the IGF1 specific binding was detectable but low (0.8 and 6.2 fmoles mg⁻¹ of proteins). In the same incubation conditions, the normal human liver, which expresses few IGF1 receptors and was used as negative control, exhibited a ¹²⁵I-IGF1 specific binding of 9.36 fmoles mg⁻¹ of proteins.

In six cases, IGF1-R were detected both in the breast carcinoma tissue and in the adjacent benign breast disease tissue, demonstrating much lower concentrations in the latter (Figure 5). Interestingly, in most breast carcinomas (15/18) it was possible to detect areas with a significantly high density of labelling. Conversely, in benign breast diseases or normal
breast (11/12) the IGF1-R labelling was diffuse and there were no areas with a higher IGF1-R concentration.

Discussion

The specificity of the 121I-IGF1 binding determined by HAA, in breast cancer sections, was similar to our previous findings using membrane preparations (Peyrat et al., 1988a). IGF1 was the most potent ligand (versus IGF2 and insulin) to inhibit the 121I-IGF1 binding. The relative affinity of receptor to IGF1, IGF2 and insulin exhibited typical type I binding site (IGF1 > IGF2 > insulin). Several groups have demonstrated that breast cancer cells secreted IGF1 binding proteins into their conditioned media (Yee et al., 1989; De Leon et al., 1989; Yee et al., 1991). The IGF binding proteins were characterised by their ability to bind radiolabelled IGF1 or IGF2 and not insulin. The results of our competition binding assays suggest the absence of IGF binding proteins on breast slide preparations. The tissue frozen sections were not fixed and it is likely that soluble binding proteins were eliminated during the incubations. This was confirmed by the low level of 121I-IGF1 binding in normal human liver which is very rich in binding proteins. The use of alpha IR-3 monoclonal antibody clearly reinforced the fact that 121I-IGF1 binding detected by autoradiographic analysis on breast cancer sections, was specific of type I IGF receptor.

We found a significant correlation between IGF1-R histoadautoradiographic and biochemical quantifications, demonstrating that it is possible to utilise HAA to assay IGF1-R. Moreover, HAA allows the tissue localisation of IGF1-R in very heterogenous tissue such as breast tumours. IGF1 specific binding is limited to the areas of breast tumours that represent target tissue for IGF1. In fact, HAA demonstrates that specific binding sites are localised on the epithelial component; whereas the stromal tissue as well as the duct lumina contained only unspecifically bound IGF1. Most of the human breast cancers studied exhibited strong IGF1 specific binding. In benign breast diseases, low levels of specific binding were detected either in dystrophic diseases, which contain few epithelial cells or in fibroadenomas, which are epithelium-rich tissues. These results suggest that proliferating epithelial cells were labelled by 121I-IGF1; it would be interesting to analyse specific IGF1 binding in epithelial atypical hyperplasias. The concept of the importance of IGF1-R as proliferative marker can be applicable for other tissues like human lung cancers (Shigematsu et al., 1990), neoplastic endometrium (Talavera et al., 1990) and colon cancer cells (Guo et al., 1990). We have some results indicating high levels of IGF1-R in neoplastic endometrium, ovaries and liver carcinoma (Figure 4). HAA also appears to have a potential interest in the analysis of the ontology of IGF1 binding in relation to the evolution of mastopathy to carcinoma, and also in the receptor quantification in tumours with a limited amount of tissue.

HAA allows precise analysis of the significance of low IGF1-R levels in the tumours. In fact, the low levels could correspond to two contrasting situations: either a diffuse labelling of the tissue (as in benign breast diseases) or a heterogeneous labelling with limited areas containing relatively high IGF1-R concentrations (as is the case for the colloid tumour). It can be proposed that in the latter situation, the tumours would present clusters of epithelial cells containing an appreciable quantity of IGF1 receptors and would develop under IGF1 stimulation. In all cancers considered as negative (<1% of HAA labelled by specific binding of low levels of localisation, <3 fmoles mg-1 protein). A detailed analysis of the sections demonstrated that, in these tumours, there were no areas with high IGF1-R concentration. In contrast, we detected by biochemical analysis five breast cancers with low IGF1-R levels (between 1 to 2%); HAA allowed the discrimination of these categories of tumours in this group. In two individual cases, the labelling was diffuse (with 1.8 and 20 fmoles mg-1 protein of specific 121I-IGF1 binding, respectively) and these tumours could be considered as negative. In other tumours, HAA demonstrated a heterogeneity of specific labelling with clusters of IGF1-R rich cells (with 44.7, 46.5 and 100 fmoles mg-1 protein of specific binding in cell clusters respectively) and the tumours were positive. Clearly, the HAA was potent in technique to reveal the presence of IGF1-R in tumours and improve the classification of these tumours as IGF1-R negative or positive. We have demonstrated that a poor prognosis is associated with negative, biochemically detected, IGF1-R (Bonnetterre et al., 1990). HAA could be useful for a better selection of IGF1-R negative tumours.

In conclusion, HAA should be highly useful for examining tumour heterogeneity with respect to IGF1-responsiveness. IGF1 is an important growth factor in breast cancer and IGF1-R is a good marker of epithelial proliferation.

This study was supported by grants from the Association pour la Recherche sur le Cancer (ARC) and the Ligue Nationale Contre le Cancer. The secretarial help of Y. Vendel is gratefully acknowledged.

References

ARTEAGA, C.L. & OSBORNE, C.K. (1989). Growth inhibition of human breast cancer cells in vitro with an antibody against the type one somatomedins receptor. Cancer Res., 49, 6237–6241.

BAXTER, R.C., MAITLAND, J.E., RAISON, R.L., REDDEL, R. & SUTHERLAND, R.L. (1987). High molecular weight somatomedin-C (IGF1) from T47-D human mammary carcinoma cells immunoreactivity and bioactivity. In E.M. Spencer (ed.), Insulin-like Growth Factors-Somatotropins, pp. 615–678. Berlin Walter de Gruyter.

BOHANNON, N.J., FIGlewicz, D.P., CORP, E.S., Wilcox, B.J., Porte, D. & Baskin, D.G. (1986). Identification of binding sites for an insulin-like growth factor (IGF1) in the median eminence of the rat brain by quantitative autoradiography. Endocrinology, 119, 943–945.

BONNETERRE, J., PEYRAT, J.P., BEUSCART, R. & DEMAILLE A. (1990). Prognostic significance of IGF1 receptors in human breast cancer. Cancer Res., 50, 6931–6935.
MURPHY, A.J., BELL, G.I. & FRIESEN, H.G. (1987). Tissue distribution of insulin-like growth factor I and II messenger ribonucleic acid in the adult rat. Endocrinology, 12, 1279–1282.

MYAL, Y., SHIU, R.P.C., BHAUMICK, B. & BALA, M. (1984). Receptor binding and growth promoting activity of insulin-like growth factor in human breast cancer cells (T47-D) in culture. Cancer Res., 44, 5486–5490.

OSBORNE, C.K., CORONADO, E.B., KITSEN, L.J., ARTEGA, C.L., FUQUA, S.A.W., MARSHALL, M. & LI, C.H. (1989). Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol. Endocrinol., 3, 1701–1709.

PEKONEN, F., PARTANEN, S., MÄKINEN, T. & RUNTANE, E.M. (1988). Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res., 48, 1343–1347.

PEYRAT, J.P., BONNETTERRE, J., BEUSCART, R., DIJANE, J. & DEMAILLE, A. (1986a). Insulin-like growth factor I receptors (IGF-I-R) in human breast cancer. Relation to estradiol and progesterone receptors. Cancer Res., 48, 6429–6433.

PEYRAT, J.P., BONNETTERRE, J., LAURENT, J.C., LOUCHEZ, M.M., AMRANI, S., LEROY-MARTIN, B., VILAIN, M.O., DELOBELLE, A. & DEMAILLE, A. (1988a). Presence and characterization of insulin-like growth factor I receptors in human benign breast disease. Eur. J. Cancer Clin. Oncol., 24, 1425–1431.

PEYRAT, J.P., BONNETTERRE, J., DUSANTER-FOURT, J., LEROY-MARTIN, B., DIJANE, J. & DEMAILLE, A. (1989). Characterization of insulin-like growth factor I receptors (IGF-I-R) in human breast cancer cells. Bull. Cancer, 76, 311–319.

POLLAK, M.N., DEPUY, J.F., MARGOLESE, R.G., BAER, K. & RICHARD, M. (1987). Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett., 38, 223–230.

POLLAK, M.N., POLYCHRONAKOS, C., YOUSEFI, S. & RICHARD, M. (1988). Characterization of insulin-like growth factor I receptor (IGF-1) receptors in human breast cancer cells. Biochem. Biophys. Res. Commun., 154, 326–331.

ROHLIK, Q.T., ADAMS, D., KULL, F.C. & JACOBS, S. (1987). An antibody to the receptor for insulin-like growth factor I inhibits the growth of MCF7 cells in tissue culture. Biochem. Biophys. Res. Commun., 149, 276–281.

ROSENBERG, R.G. & HINTZ, R.L. (1988). Somatomedin receptors and function and regulation. In Conn, P.M. (ed.), The Receptors, Vol. 3, pp. 281–329. New York: Academic Press.

SHIGEMATSU, K., NIWA, M., KURIHARA, M., YAMASHITA, K., KAWAI, K. & TSUCHIYAMA, H. (1989). Receptor autoradiographic localization of insulin-like growth factor-I(IGF-I) binding sites in human fetal and adult adrenal glands. Life Sci., 45, 383–389.

SHIGEMATSU, K., KATAOKA, Y., KAMIO, T., KURIHARA, M., NIWA, M. & TSUCHIYAMA, H. (1990). Partial characterization of insulin-like growth factor I in human primary lung cancers using immunohistochemical and receptor autoradiographic techniques. Cancer Res., 50, 2481–2484.

TALAVERA, F., REYNOLDS, R.K., ROBERTS, J.A. & MENON, K.M.J. (1990). Insulin-like growth factor I receptors in normal and neoplastic human endometrium. Cancer Res., 50, 3041–3044.

YEE, D., CULLEN, K.J., PAIK, S., PERDUE, J.F., HAMPTON, B., SCHWARTZ, A., LIPPMAN, M.E. & ROSEN, N. (1988). Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res., 48, 6691–6696.

YEE, D., FAVONI, R.E., LIPUI, B., CULLEN, K.J., LEBOVIC, G.S., HUFF, K.K., LEE, P.D.K., LEE, Y.L., POWELL, D.R., DICKSON, R.B., ROSEN, N. & LIPPMAN, M.E. (1989). The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells. Biochem. Biophys. Res. Commun., 158, 38–44.3024.

YEE, D., FAVONI, R.E., LIPPMAN, M. & POWELL, D.R. (1991). Identification of insulin-like growth factor binding protein in breast cancer cells. Breast Cancer Res. Treat., 18, 3–10.

ZAPP, J. & FROESCH, E.R. (1986). Pathophysiological and clinical aspects of the insulin-like growth factors. Hormone Res., 24, 160–165.